Lead for Infectious Diseases

Lead for COVID-19 vaccines

Led the global HTA strategy for the launch of the first long-acting HIV treatment and pre-exposure prophylaxis

Launching Shingrix, the vaccine that protects elderly against shingles, submitted reimbursement dossiers for Bexsero which protects infants from deadly meningitis and its long-term sequelae, and supported all countries with tenders for pneumococcal vaccines.

Through my affiliations with Imperial College London and Laval University Canada, I provided evidence for recommendations regarding HPV vaccination programs. I developed several mathematical models to predict the cost-effectiveness of HPV vaccination and the agent-based model, “HPV-ADVISE”, has been used by decision makers in Canada, Europe and the US to explore and optimize vaccination scenarios. The work involves integrating data from different sources (economic, political, epidemiological, demographic, clinical) to address specific policy questions and communicate results in international conferences and high-impact scientific journals. As a first author, I have been published in The American Journal of Epidemiology, Vaccine and The Journal of the National Cancer Institute, and each year I was invited to speak at IPV and Eurogin.The results of my models have been presented and/or included in the guidelines of the following agencies:2012-13 - CDC, United StatesCenters for Disease Control and PreventionEvaluation of the nonavalent vaccine using HPV-ADVISE2012 - HCSP CSMT, FranceHaut Conseil de la santé publique, Commission spécialisée Maladies transmissibles, Comité technique des vaccinations Presentation of specific vaccination scenarios2012 - NACI, CanadaNational Advisory Committee in Immunization Quadrivalent vs. bivalent vaccines in Canada 2012 - INVS, FranceInstitut de Veille Sanitaire Presentation of HPV-ADVISE2010 - WHO, Developing CountriesWorld Health OrganizationHPV vaccination in developing countries, Invited Expert2007 - CIQ, Quebec, CanadaQuebec Immunisation Committee Potential cost-effectiveness of HPV vaccination, Invited Expert

2012-13 - Merck & Co., Inc. - United StatesMerck’s HPV Global Advisory Board: Provide advice, counsel and assistance in the development, planning, and execution of commercial and scientific initiatives related to MSD’s HPV program.2012 - MSD International GmbH - SwitzerlandMedical education program entitled "MSD Expert Forum on HPV" (Budapest, Hungary): Workshop “Understand the differences in HECON models”.2011 - Merck & Co., Inc. - United StatesExpert input forum entitled "Integration Screening and Vaccination for 2nd generation HPV Vaccine" (Berlin, Germany) 2011-12 - Merck & Co., Inc. - United StatesProvide advice and guidance on health economic modeling for evaluating HPV vaccination programs, prepare for the V503 review by the ACIP and FDA.2010-11 - Sanofi Aventis MSD - FranceAdvice and assistance in the development of mathematical models

- Responsible for the purity of HBV surface antigen- FDA audits- In charge of validations and legal compliance